These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis. Zhou S; Gao J; Xu X Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196 [TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516 [TBL] [Abstract][Full Text] [Related]
8. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Eadie JA; Ip MS; Kulkarni AD Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721 [TBL] [Abstract][Full Text] [Related]
9. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion. Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794 [TBL] [Abstract][Full Text] [Related]
11. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study. Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T; Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500 [TBL] [Abstract][Full Text] [Related]
13. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis. Spooner K; Hong T; Fraser-Bell S; Chang AA Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837 [TBL] [Abstract][Full Text] [Related]